KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Capital Employed (2016 - 2025)

Arbutus Biopharma's Return on Capital Employed history spans 12 years, with the latest figure at 0.49% for Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 14.0% year-over-year to 0.49%; the TTM value through Sep 2025 reached 0.49%, up 14.0%, while the annual FY2024 figure was 0.62%, 9.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 0.49% at Arbutus Biopharma, up from 0.57% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.35% in Q3 2022 and bottomed at 0.79% in Q1 2025.
  • The 5-year median for Return on Capital Employed is 0.56% (2025), against an average of 0.55%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 93bps in 2021 before it dropped -21bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.5% in 2021, then grew by 21bps to 0.39% in 2022, then crashed by -54bps to 0.61% in 2023, then fell by -5bps to 0.63% in 2024, then rose by 22bps to 0.49% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Return on Capital Employed are 0.49% (Q3 2025), 0.57% (Q2 2025), and 0.79% (Q1 2025).